Unknown

Dataset Information

Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan.


ABSTRACT:

Introduction

Daprodustat is an approved treatment for anemia of chronic kidney disease (CKD) in Japan.

Methods

This post hoc analysis evaluated pooled safety data for daprodustat from 3 phase 3 Japanese studies in dialysis-dependent and nondialysis patients with anemia of CKD.

Results

Median drug exposure duration was 365 days for both daprodustat (N = 369) and injectable erythropoiesis-stimulating agent (ESA, N = 285). The incidence per 100 patient-years of on-therapy adverse events (AEs) was 363.1 and 306.4 in the daprodustat and ESA groups, respectively. The incidence per 100 patient-years of thromboembolic and retinal events were 5.55 and 6.91 (daprodustat) and 6.28 and 7.46 (ESA), respectively. Cardiovascular and malignancy events were similar between groups, alt

SUBMITTER: Nangaku M 

PROVIDER: S-EPMC9790622 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature